Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette–Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer

A significant number of patients with intermediate- or high-risk bladder cancer treated with intravesical Bacillus Calmette–Guérin (BCG) immunotherapy are non-responders to this treatment. Since we cannot predict in which patients BCG therapy will fail, markers for responders are needed. UroVysion(®...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Med Oncol
Main Authors: Liem, Esmee I. M. L., Baard, Joyce, Cauberg, Evelyne C. C., Bus, Mieke T. J., de Bruin, D. Martijn, Laguna Pes, M. Pilar, de la Rosette, Jean J. M. C. H., de Reijke, Theo M.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2017
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581817/
https://ncbi.nlm.nih.gov/pubmed/28866819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-017-1033-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados